Genting Berhad's Earnings Recover, Shares Lag
Genting Berhad's Earnings Recover, Shares Lag
Genting Bhd (GENT MK) experienced a lacklustre year in terms of share price performance, despite a strong earnings recovery driven by increased visitor numbers at its Resorts World Genting and Resorts World Sentosa properties, as highlighted in Maybank Investment Bank's (Maybank) recent report today (July 15, Monday).
馬來西亞雲頂集團（Genting Bhd）股價表現平平，儘管5月銀行投資銀行（Maybank）近日發佈的報告指出，由雲頂高地和聖淘沙名勝世界的入場人數增加推動收益強勁復甦。
Maybank maintains a BUY rating on Genting Bhd (GENT MK) with a MYR5.84 SOP-TP. Analysts at Maybank believe the recent share price weakness, amidst a 2% decline year-to-date compared to an 11% increase in the FBMKLCI, is unjustified. They point to the robust earnings recovery nearing pre-COVID levels and the potential positive impact of a stronger Malaysian Ringgit (MYR) against the USD, historically beneficial for Genting's valuations.
馬來亞銀行維持買入評級，目標股價爲5.84馬幣。馬來亞銀行的分析師認爲最近股價的疲軟不公平，儘管相比FBMKLCI指數上漲11%，股票今年以來已下跌2%。他們指出，強勁的盈利恢復接近疫情前水平，以及馬幣對美元的潛在正面影響對雲頂休閒的估值有益且歷史悠久。
Maybank notes that Genting Bhd (GENT MK) stands to benefit from a potential regulatory approval for TauRx's experimental drug by year-end, with a hypothetical valuation scenario of USD15 billion for TauRx underpinning a significant upside potential to their SOP-TP of MYR9.35.
馬來亞銀行指出，TauRx實驗藥物年底前有望獲得監管批准，假設TauRx的估值場景爲150億美元，將爲其9.35馬幣目標價提供巨大的上行潛力。
Investors keen on Genting Bhd (GENT MK) might find Maybank's optimistic outlook compelling, given the anticipated earnings rebound and potential catalysts from TauRx's drug approval, coupled with expectations of MYR appreciation against the USD.
對於雲頂休閒感興趣的投資者，可能會發現馬來亞銀行的樂觀前景令人信服，預計盈利會反彈，並有TauRx藥物批准的潛在催化劑，再加上亞洲貨幣兌美元的升值預期。